Medicamen Biotech Ltd
Medicamen Biotech Ltd develops and markets a wide range of branded and generic formulations in the pharmaceutical industry.[1]
- Market Cap ₹ 486 Cr.
- Current Price ₹ 384
- High / Low ₹ 904 / 355
- Stock P/E 43.3
- Book Value ₹ 158
- Dividend Yield 0.26 %
- ROCE 10.4 %
- ROE 8.67 %
- Face Value ₹ 10.0
Pros
- Company is expected to give good quarter
Cons
- Company has a low return on equity of 9.56% over last 3 years.
- Dividend payout has been low at 8.93% of profits over last 3 years
- Company has high debtors of 169 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
---|---|---|---|---|---|---|
123 | 125 | 113 | 115 | 141 | 171 | |
105 | 106 | 93 | 91 | 117 | 148 | |
Operating Profit | 17 | 20 | 20 | 24 | 24 | 23 |
OPM % | 14% | 16% | 17% | 21% | 17% | 13% |
4 | 2 | 1 | 2 | 2 | 2 | |
Interest | 1 | 1 | 2 | 2 | 3 | 3 |
Depreciation | 2 | 2 | 3 | 6 | 6 | 7 |
Profit before tax | 18 | 18 | 16 | 18 | 17 | 15 |
Tax % | 31% | 26% | 26% | 18% | 14% | |
12 | 13 | 12 | 15 | 15 | 11 | |
EPS in Rs | 10.28 | 10.88 | 9.93 | 12.20 | 11.73 | 9.16 |
Dividend Payout % | 10% | 5% | 10% | 8% | 9% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 4% |
TTM: | 37% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 3% |
TTM: | -18% |
Stock Price CAGR | |
---|---|
10 Years: | 42% |
5 Years: | -5% |
3 Years: | -10% |
1 Year: | -41% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 10% |
Last Year: | 9% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
---|---|---|---|---|---|---|
Equity Capital | 12 | 12 | 12 | 12 | 13 | 13 |
Reserves | 75 | 109 | 121 | 134 | 181 | 187 |
12 | 11 | 19 | 26 | 26 | 29 | |
38 | 49 | 42 | 53 | 59 | 68 | |
Total Liabilities | 137 | 181 | 194 | 226 | 279 | 297 |
24 | 34 | 90 | 92 | 93 | 93 | |
CWIP | 15 | 40 | 0 | 0 | 0 | 0 |
Investments | 0 | 0 | 0 | 0 | 0 | 0 |
97 | 107 | 104 | 133 | 186 | 204 | |
Total Assets | 137 | 181 | 194 | 226 | 279 | 297 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|
4 | 13 | 13 | 4 | -6 | |
-15 | -37 | -18 | -8 | -6 | |
-4 | 19 | 6 | 4 | 29 | |
Net Cash Flow | -14 | -5 | 1 | -0 | 17 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|
Debtor Days | 129 | 145 | 170 | 200 | 169 |
Inventory Days | 67 | 78 | 27 | 188 | 228 |
Days Payable | 134 | 173 | 169 | 302 | 241 |
Cash Conversion Cycle | 62 | 51 | 28 | 86 | 156 |
Working Capital Days | 151 | 152 | 161 | 208 | 216 |
ROCE % | 16% | 13% | 12% | 10% |
Documents
Announcements
- Announcement under Regulation 30 (LODR)-Trading Plan under SEBI (PIT) Regulations, 2015 2d
-
Announcement Under Regulation 30 Of SEBI (LODR) Regulations, 2015
26 Mar - FDA has conducted audit of Oncology Plant, Haridwar. We are awaiting the plant approval from FDA. Meanwhile we have submitted dossiers for 10 oncology products …
-
Announcement under Regulation 30 (LODR)-Acquisition
23 Mar - Disclosure under Regulation 29(2) of SAST Regulations, 2011 received from Shivalik Rasayan Limited for purchase of 200000 Equity Shares from open market
-
Announcement under Regulation 30 (LODR)-Acquisition
23 Mar - Disclosure under regulation 29(2) of SAST Regulations, 2011 received from Growel Remedies Limited for sale of 200000 Equity Shares
-
Announcement under Regulation 30 (LODR)-Trading Plan under SEBI (PIT) Regulations, 2015
23 Mar - Form C pursuant to Regulation 7(2)(a) of PIT Regulations, 2015, received from Shivalik Rasayan Limited for purchase of 200000 Equity Shares from open market.
Annual reports
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
-
Financial Year 2009
from bse
Product Offerings
The Company manufactures formulations for anti-retroviral, oncology, cardiovascular, diabetic and hypertension, nutraceutical, and other products. Its key products are Efavirenz, Tenofovir (TDF), Gemcitabine, and Finished Dosage Forms (FDF) of these Products and Bio-Technology. [1]